Generation of human induced pluripotent stem cell line UNIGEi001-A from a 2-years old patient with Mucopolysaccharidosis type IH disease by Lito, Silvin et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Generation of human induced pluripotent stem cell line UNIGEi001-A from
a 2-years old patient with Mucopolysaccharidosis type IH disease
Lito, Silvin ; Burda, Patricie ; Baumgartner, Matthias ; Sloan-Béna, Frédérique ; Táncos, Zsuzsanna ;
Kobolák, Julianna ; Dinnyés, András ; Krause, Karl-Heinz ; Marteyn, Antoine
DOI: https://doi.org/10.1016/j.scr.2019.101604
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-181006
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Lito, Silvin; Burda, Patricie; Baumgartner, Matthias; Sloan-Béna, Frédérique; Táncos, Zsuzsanna; Kobolák,
Julianna; Dinnyés, András; Krause, Karl-Heinz; Marteyn, Antoine (2019). Generation of human induced
pluripotent stem cell line UNIGEi001-A from a 2-years old patient with Mucopolysaccharidosis type IH
disease. Stem Cell Research, 41:101604.
DOI: https://doi.org/10.1016/j.scr.2019.101604
Contents lists available at ScienceDirect
Stem Cell Research
journal homepage: www.elsevier.com/locate/scr
Lab Resource: Single Cell Line
Generation of human induced pluripotent stem cell line UNIGEi001-A from
a 2-years old patient with Mucopolysaccharidosis type IH disease
Silvin Litoa, Patricie Burdab, Matthias Baumgartnerb, Frédérique Sloan-Bénac, Zsuzsanna Táncosd,
Julianna Kobolákd, András Dinnyésd,e, Karl-Heinz Krausea, Antoine Marteyna,⁎
a Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
bDivision of Metabolism and Children's Research Center, University Children's Hospital, Zürich CH-8032, Switzerland
c Service of Genetic Medicine, Geneva University Hospitals, Geneva, Switzerland
d BioTalentum Ltd., Gödöllő, Hungary
eMolecular Animal Biotechnology Laboratory, Szent István University, Gödöllő, Hungary
A B S T R A C T
Mucopolysaccharidosis type I-Hurler (MPS1-H) is the most severe form of inherited metabolic diseases caused by mutations in the IDUA gene. The resulting
deﬁciency of alpha L-iduronidase enzyme leads to a progressive accumulation of glycosaminoglycans in lysosomes which damages multiple organs and highly
reduces life expectancy of aﬀected children. Skin ﬁbroblasts of a 2-year-old MPS1-H male, carrying two mutations in each IDUA alleles (H358_T364del; W402X),
were reprogrammed into induced pluripotent stem cells (iPSCs) using the CytoTune-iPS Sendai Reprogramming method applying Yamanaka-factors (OCT4, SOX2,
KLF4, c-MYC). iPSCs expressed pluripotency transcription factors while iPSC-derived embryoid bodies reveal markers of the three germ layers.
Resource Table:
Unique stem cell line
identiﬁer
UNIGEi001-A
Alternative name(s) of
stem cell line
MPS1-H.2y.S4
Institution University of Geneva (UNIGE), Geneva, Switzerland
Contact information of
distributor
Karl-Heinz Krause; Karl-Heinz.Krause@unige.ch
Type of cell line iPSC
Origin human
Additional origin info Age: 2
Sex: male
Ethnicity: Caucasian
Cell Source Skin ﬁbroblasts
Clonality Clonal
Method of reprogram-
ming
Sendai virus
Genetic modiﬁcation Yes
Type of modiﬁcation Hereditary
Associated disease Mucopolysaccharidosis type I (MPS1), also named Hurler
syndrome
Gene/locus Two diﬀerent mutations were identiﬁed. One in each
IDUA single allele (Cytogenetic location: 4p16.3)
- In exon 8: NM_000203.5(IDUA):c.1073_1093del
(p.His358_Thr364del)
- In exon 9: NM_000203.4(IDUA):c.1205 G>A
(p.Trp402Ter)
Method of modiﬁcation Not applicable
Name of transgene or r-
esistance
Not applicable
Inducible/constitutive s-
ystem
Not applicable
Date archived/stock da-
te
July 2014
Cell line repository/ba-
nk
https://hpscreg.eu/cell-line/UNIGEi001-A
Ethical approval Parents of patient informed consent obtained.
Ethical approval was obtained from the competent
authority to establish and maintain human iPSC lines (in
Hungary: Medical Research Council (in Hungarian:
Egészségügyi Tudományos Tanács – Tudományos és
Kutatásetikai Bizottság; ETT-TUKEB) ETT-TUKEB 834/PI/
09, 8-333/2009-1018EKU);
1. Resource utility
Mucopolysaccharidosis type I (MPS1), or Hurler syndrome, is a rare
and severe lysosomal storage disorder progressively aﬀecting many
organs and leading to death during childhood if treatments are delayed.
Induced pluripotent stem cells, generated from MPS1 patient may re-
present a valuable resource for modelling the disease and deciphering
pathological processes.
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2. Resource details
Mucopolysaccharidosis type I-Hurler (MPS1-H), the most severe
form of MPSs, is a rare lysosomal storage disorder caused by the deﬁ-
ciency of alpha L-iduronidase (IDUA), which is the needed enzyme to
catabolize glycosaminoglycans (GAGs) (Giugliani et al., 2010). Im-
pairment of its activity leads to progressive accumulation of GAGs
followed by dysfunction of many biological systems and organs, such as
aﬀections of cardiovascular, respiratory and central nervous system.
Without enzyme replacement therapy or hematopoietic stem cell
transplantation, this autosomal recessive disorder is fatal in early
childhood (before 5 years old) (Tolar et al., 2008).
Skin ﬁbroblasts were isolated from skin tissues of a 2-year-old male,
MPS1-H diagnosed by Division of Metabolism and Children's Research
Center of University Children's Hospital of Zürich (Switzerland). Loss-
of-function of alpha L-iduronidase and resulting MPS1-H symptoms
have genetically been associated to the presence of two distinct muta-
tions distributed on the two alleles of the IDUA gene
(NM_000203.5(IDUA):c.1073_1093del (p.His358_Thr364del) and
NM_000203.4(IDUA):c.1205 G>A (p.Trp402Ter)) (Table 1, Fig. 1A).
MPS1 ﬁbroblasts have been reprogrammed into MPS1 iPSC line by
using integration-free CytoTune-iPS Sendai Reprogramming system,
using the Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC)
(Takahashi et al., 2007). After few passages, newly generated MPS1-
H.2y.S4 iPSC were fully characterized. First, the genetic identity of
isolated iPSC and the parental MPS1 patient ﬁbroblasts have been
conﬁrmed by STR analysis (Table 1). Both IDUAmutations, identiﬁed in
ﬁbroblasts, were also detected in resulting iPSC (Fig. 1A). At passage 12,
normal karyotype and genome integrity were assessed by Comparative
Genomic Hybridization (CGH) array. While this technique cannot
identify balanced translocations, cells present a normal karyotype
without genomic imbalances (Fig. 1B). Performance of a PCR-based
Mycoplasma test certiﬁed our cell culture as mycoplasma-free (Fig. S1).
Based on the clear borders of colonies that are composed of small,
tightly packed cells with large nucleoli, these cells display morpholo-
gical features and organization of pluripotent stem cells (Fig. 1C).
Although alkaline phosphatase activity was detected in the colonies
(Fig. 1D), validation of the reprogramming of ﬁbroblasts into bona ﬁde
iPSC was also conﬁrmed by the expression of pluripotency transcription
factors by ﬂow cytometric analysis (Fig. 1E) and immunoﬂuorescence
staining (Fig. 1F). Indeed, more than 94% of cells were positive for
NANOG, OCT4 and SOX2 by FACS analysis.
In order to further conﬁrm their pluripotency, embryoid bodies
(EBs) have been generated from the cells (Fig. 1H) and were sponta-
neously diﬀerentiated in vitro for 24 days. Diﬀerentiation potential of
the cells was validated by the expression of speciﬁc markers of the three
germ layers, both by immunoﬂuorescence staining (Fig. 1I) and PCR
(Fig. 1). Expression of SOX17 and AFP revealed a diﬀerentiation toward
the endoderm, while ACTA2 and FOXA2 highlighted a mesodermal
pattern and ﬁnally TUBB3 and MAP1B the presence of ectoderm germ
layer.
In conclusion, our newly reprogrammed MPS1-H.2y.S4 iPSC pre-
sents all features of pluripotent stem cells and is ready to be used for
MPS1-H modelling or for drug discovery studies.
3. Materials and methods
3.1. Human dermal ﬁbroblast reprogramming
Fibroblasts, isolated from the skin biopsy of a 2-year-old male MPS1
patient, were expanded in ﬁbroblast medium (DMEM, 10% fetal bovine
serum (FBS), 1% Non-Essential amino acids (NEAA), 1% Sodium pyr-
uvate, 1% Glutamine and 1% Pen/Strep). An amount of 2× 105 MPS1
ﬁbroblasts were plated on 6-well plate and transduced with the
Yamanaka factors (OCT3/4, NANOG, KLF4, c-MYC), using CytoTune®-
iPS Sendai Reprogramming Kit (Thermo Fisher Scientiﬁc) at an MOI of
5:5:3. Cells were maintained in ﬁbroblast medium until D4, when
medium was switched to mTeSR™1 medium (StemCell Technologies).
Colonies were picked manually between D19 and D24 on Matrigel®-
coated culture dishes and were routinely passaged every 5–6 days, at a
split ratio of 1:5, using 0.5mM EDTA (Sigma-Aldrich). All cells were
cultured at 37 °C in humidiﬁed atmosphere containing 5% CO2.
Table. 1
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Microscopic observation Phase
contrast images
Normal Fig. 1C
Phenotype Qualitative analysis
Immunocytochemistry
Positive for OCT4, NANOG, SOX2 Fig. 1F
Quantitative analysis Flow cytometry Expression of OCT4, NANOG and SOX2 (>94%) Fig. 1E
Genotype CGH array Normal male karyotype: arr(1–22)x2,(XY)x1 Fig. 1B
Analytic resolution 200 kb
No pathogenic or non-pathogenic copy number variant detected
Identity Microsatellite PCR (mPCR) OR STR
analysis
N/A N/A
6 loci tested, all matched Available with the
authors
Mutation analysis (IF
APPLICABLE)
Sequencing Two diﬀerent mutations were identiﬁed. They are distributed on each IDUA allele
(Cytogenetic location: 4p16.3):
Fig. 1A
- In exon 8: NM_000203.5(IDUA):c.1073_1093del (p.His358_Thr364del)
- In exon 9: NM_000203.4(IDUA):c.1205 G>A (p.Trp402Ter)
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma PCR-based Mycoplasma test Supplementary Fig. 1
Diﬀerentiation potential Embryoid body formation Phase
contrast images
Normal morphology of Embryoid bodies Fig. 1H
PCR Negative expression Pluripotent marker Positive expression of speciﬁc markers of
the three germ layers
Fig. 1G
Spontaneous in vitro diﬀerentiation
into the three germ layers
In vitro diﬀerentiation into derivatives of the three germ layers: endoderm, α-
fetoprotein (AFP); mesoderm, Forkhead Box A2 (FOXA2); and ectoderm, β3-
tubulin (TUBB3)
Fig. 1I
Donor screening
(OPTIONAL)
HIV 1+2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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Fig. 1. Characterization of MPS1-H.2y.S4 iPSC line. (A) Sanger sequencing of IDUA regions revealing two distinct mutations associated to MPS1-H in parental MPS1
patient ﬁbroblasts and in the newly established MPS1 iPSC line. (B) CGH array of MPS1 iPSC line showed normal karyotype of a male subject. (C) Generated MPS1
iPSC line cells displayed morphological features of pluripotent stem cells and were (D) alkaline phosphatase positive. (E) FACS analysis and (F) immunoﬂuorescence
staining revealed the presence of high levels of the pluripotent markers NANOG, OCT4 and SOX2. Nuclei was counterstained with Hoechst. (G) PCR analysis
conﬁrmed the expression of pluripotent transcription factors NANOG and OCT4 in iPSC and the expression of speciﬁc markers of endoderm (SOX17 and AFP),
mesoderm (ACTA2 and FOXA2), and ectoderm (TUBB3 and MAP1B) into iPSC-derived embryoid bodies. GAPDH was used as housekeeping gene. (H) Floating
embryoid bodies 2 days after aggregation. (I) Diﬀerentiation potential of MPS1 iPSC line was conﬁrmed by immunoﬂuorescence staining of spontaneously diﬀer-
entiated embryoid bodies into the three germ layers at 24 days: endoderm (AFP), mesoderm (FOXA2), and ectoderm (TUBB3). Nuclei was counterstained with
Hoechst. All scale bars = 50 µm.
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3.2. Pluripotency ﬂow cytometric assay
Expression of pluripotent stem cell transcription factors of MPS1-
H.2y.S4 iPSC was validated by ﬂow cytometry, using BD Stemﬂow
Human Pluripotent Stem Cell Transcription Factor Analysis Kit® (BD
Biosciences) according to the manufacturer's instructions. Acquisition
was performed using ACCURI 6 ﬂow cytometer. Data analysis was
carried out with BD Accuri C6 software.
3.3. Alkaline phosphatase staining
iPSC colonies were ﬁxed with 4% paraformaldehyde (PFA) for
10min at room temperature (RT), then incubated with NBT solution
(Sigma-Aldrich) for 30min at RT. Stained colonies were observed under
Eclipse Ts2 inverted microscope (Nikon). Scale bar = 50 µm.
3.4. Embryoid bodies assay
The iPSC clones were spontaneously diﬀerentiated into the three
embryonic germ layers. Colonies were dissociated with Accutase® for
5min at 37 °C and uniform EBs were formed by plating 1000 cells/
microwell of AggreWell™ plates, in mTeSR™1 medium supplemented
with 10 µM of Rock inhibitor (Abcam Biochemicals). One day after, EB
were collected and cultured in rotation (60 rpm, orbital shaker) for 5
days in DMEM supplemented with 20% FBS, 1% NEAA, 1% Glutamine,
1% Pen/Strep and 0.1 mM β-mercaptoethanol. On D6, EBs were
transferred to gelatin-coated plates and maintained in same medium for
additional 19 days. Medium was changed every 2–3 days.
3.5. Immunocytochemistry
Following 4% PFA ﬁxation for 10min at RT, iPSC colonies or em-
bryoid bodies were incubated 30min at RT in blocking solution con-
stituted by PBS containing 0.1% Triton X-100 and 3% BSA, to block
nonspeciﬁc binding. Cells were then incubated 1 hour at RT, with the
speciﬁc primary antibodies respectively (Table 2), diluted in the
blocking solution. Appropriate secondary antibodies were incubated for
45min at RT. Nuclei were stained with DAPI. Images were captured
with a LSM-700 (Zeiss) confocal microscope. Scale bar = 50 µm.
3.6. RNA extraction and RT-PCR
RNA was extracted by using RNeasy Mini kit (Qiagen) and reverse
transcription was performed using the PrimeScript RT Reagent Kit
(Takara) according to the manufacturer's instructions. PCR ampliﬁca-
tion was performed with a T3 Thermocycler PCR system (Biometra), by
using Taq DNA Polymerase (Qiagen). The temperature cycling protocol
was set as follows: initial degeneration step, 3 min at 95 °C; followed by
35 cycles of denaturation: 30 s at 95 °C; annealing: 30 s at 60 °C; ex-
tension, 45 s at 72 °C; ﬁnal holding, 10min at 72 °C. Primers are listed
in Table 2.
3.7. Identiﬁcation of MPS1 mutations
Genomic DNA was isolated from MPS1 ﬁbroblasts and MPS1 iPSC
by using the DNeasy® Blood & Tissue kit (Qiagen). Genotyping primers
localized on intron 7 and exon 9 (Table 2) were used to amplify by PCR,
the region of IDUA gene containing both mutations. PCR ampliﬁcation
was performed with a T3 Thermocycler PCR system (Biometra), by
using Q5® High-Fidelity DNA Polymerase (New England Biolabs). The
thermal cycling was performed as follows: initial degeneration step,
1 min at 95 °C; 35 cycles (1 min at 95 °C; 1min at 58 °C; 1min at 72 °C);
and a ﬁnal holding, 10min at 72 °C. PCR products were puriﬁed on 1%
agarose gel before sequencing. To determine the allelic distribution of
the 2 mutations further sequencing of TOPO cloned single PCR-frag-
ments was performed.
3.8. CGH array
Oligonucleotide array-CGH was performed with the Human CGH
Microarray Kit 4× 44 K (Agilent Technologies). Data analysis was
carried out with the Agilent Genomic Workbench software v6.5. Results
Table. 2
Reagents details.
Antibodies used for immunocytochemistry/ﬂow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency marker (IF) Rabbit anti-OCT4 1:100 abcam, Cat# ab18976, RRID: AB_444,714
Pluripotency marker (IF) Mouse anti-SOX2_[20G5] 1:200 abcam, Cat# ab171380, RRID: AB_2,732,072
Pluripotency marker (IF) Goat anti-NANOG 1:100 Thermo Fisher Scientiﬁc, Cat# PA5-18,406, RRID: AB_10,985,008
Endodermal marker (IF) Mouse anti-AFP 1:250 Santa Cruz, Cat# Sc-8399, RRID: AB_626,665
Mesodermal marker (IF) Mouse anti-FOXA2 1:100 Santa Cruz, Cat# Sc-101,060, RRID: AB_1,124,660
Ectodermal marker (IF) Mouse anti-β3-tubulin (TUBB3) 1:200 Sigma-Aldrich, Cat# T8660, RRID: AB_477,590
Primers
Target Forward/Reverse primer (5′−3′)
Pluripotency marker (PCR) NANOG (138 bp) GATTTGTGGGCCTGAAGAAA/ TTGGGACTGGTGGAAGAATC
Pluripotency marker (PCR) OCT4 (81 bp) AGTGCCCGAAACCCACACTG / ACCACACTCGGACCACATCCT
Housekeeping gene (PCR) GAPDH (226 bp) GAAGGTGAAGGTCGGAGTC / GAAGATGGTGATGGGATTTC
Targeted mutation sequencing IDUA_int.7_Fwd CCACCTTCCTCCCGAGAC
(683 bp)
IDUA_ex.9_Rev GTCGTCGCTCGCGTAGAT
Endodermal marker (PCR) SOX17 (374 bp) GTGAATCTCCCCGACAGC/ TGTTTTGGGACACATTCAAAGC
Endodermal marker (PCR) AFP (301 bp) AGAGTTGCTAAAGGATACCAGGA/ AGGCCAATAGTTTGTCCTCAC
Mesodermal marker (PCR) ACTA2 (228 bp) AATACTCTGTCTGGATCGGTGGCT / ACGAGTCAGAGCTTTGGCTAGGAA
Mesodermal marker (PCR) FOXA2 (98 bp) TGCACTCGGCTTCCAGTATG/ GGAGGAGTAGCCCTCGG
Ectodermal marker (PCR) TUBB3 (103 bp) GGCCTGACAATTTCATCTTTGG/ ACCACATCCAGGACCGAATC
Ectodermal marker (PCR) MAP1B (87 bp) CTGTGGAAAAGGCAGCAAAAC/ CAGCATTCTTGGTCTCCTTGTCT
PCR-based mycoplasma mycoplasma (500 bp) GGCGAATGGGTGAGTAACACG/ CGGATAACGCTTGCGACCTAT
ribosomal protein L32 (housekeeping gene) (350 bp) GTGAAGCCCAAGATCGTCAA/ TTGGTGACTCTGATGGCCAG
Short tandem repeat (STR) analysis D4S2364 [FAM]-CTAGGAGATCATGTGGGTATGATT / GCAGTGAATAAATGAACGAATGGA
D2S441 [VIC]-CTGTGGCTCATCTATGAAAACTT/ GAAGTGGCTGTGGTGTTATGAT
D1S1677 [VIC]-TTCTGTTGGTATAGAGCAGTGTTT/ GTGACAGGAAGGACGGAATG
D10S1248 [FAM]-TTAATGAATTGAACAAATGAGTGAG/ GCAACTCTGGTTGTATTGTCTTCAT
D14S1434 [VIC]-TGTAATAACTCTACGACTGTCTGTCTG/ GAATAGGAGGTGGATGGATGG
D22S1045 [VIC]-ATTTTCCCCGATGATAGTAGTCT/ GCGAATGTATGATTGGCAATATTTTT
S. Lito, et al. Stem Cell Research 41 (2019) 101604
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are given in GRCh37/hg19 genome version.
3.9. PCR-based mycoplasma test
20 000 cells were collected during passage. Cells have been lysed
with 200 µg/ml of proteinase K in DirectPCR Lysis Reagent (Viagen
Biotech) for 1 h at 56 °C and 45min at 85 °C. Two PCR were performed
from resulting lysate with speciﬁc primers of mycoplasma and ribo-
somal protein L32, listed in Table 2.
3.10. Short tandem repeat (STR) analysis
PCR ampliﬁcation of STR loci was achieved as described in Coble
et al. (Coble M.D, Butler J.M. J Forensic Sci 2005). The allelic ladders
were separated electrophoretically using size Standard GeneScan
LIZ500 (Applied Biosystems). Sequencing was analyzed using Applied
Biosystems 3730XL DNA Analyzer. with the following conditions: in-
jection time, 10 s; injection voltage, 1.6 kV; run time, 2100s; run vol-
tage, 15 kV; capillary length, 50 cm; polymer, POP7; ﬁlter, Dye Set G5.
The primer sequence are listed in Table 2.
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